Cargando…

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study

AIMS: Anaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic heart failure (CHF). We investigated the effects of i.v. iron in iron-deficient CHF patients on renal function, and the efficacy and safety of this therapy in patients with renal dysfunction. METHODS AND RESUL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ponikowski, Piotr, Filippatos, Gerasimos, Colet, Josep Comin, Willenheimer, Ronnie, Dickstein, Kenneth, Lüscher, Thomas, Gaudesius, Giedrius, von Eisenhart Rothe, Barbara, Mori, Claudio, Greenlaw, Nicola, Ford, Ian, Macdougall, Iain, Anker, Stefan D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413361/ https://www.ncbi.nlm.nih.gov/pubmed/25683972 http://dx.doi.org/10.1002/ejhf.229

Ejemplares similares

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2013)

The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study
por: Comin-Colet, Josep, et al.
Publicado: (2013)

Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR‐HF substudy
por: Okonko, Darlington O., et al.
Publicado: (2019)

Rationale and design of Ferinject(®) Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia
por: Anker, Stefan D., et al.
Publicado: (2009)

Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK
por: Gutzwiller, Florian S., et al.
Publicado: (2012)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency
por: Anker, Stefan D., et al.
Publicado: (2022)

Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
por: Metra, Marco, et al.
Publicado: (2022)

Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
por: Rosano, Giuseppe, et al.
Publicado: (2023)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial
por: Anker, Stefan D., et al.
Publicado: (2015)

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
por: Jankowska, Ewa A, et al.
Publicado: (2011)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

Hypophosphatemia in children treated with ferric carboxymaltose
por: Posod, Anna, et al.
Publicado: (2020)

The Future of Telemedicine in the Management of Heart Failure Patients
por: Silva-Cardoso, José, et al.
Publicado: (2021)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
por: Fang, Wendy, et al.
Publicado: (2019)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
por: Steinmetz, T., et al.
Publicado: (2013)

Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women
por: Rathod, Setu, et al.
Publicado: (2015)

Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding
por: Ballester-Clau, Raquel, et al.
Publicado: (2019)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
por: Diebold, Matthias, et al.
Publicado: (2019)

Fatal anaphylactic reaction due to ferric carboxymaltose: A case report
por: Arıcı, Aylin Mualla, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Efficacy and Safety of Treatment With Ferric Carboxymaltose in Patients With Cirrhosis and Gastrointestinal Bleeding
por: Ballester-Clau, Raquel, et al.
Publicado: (2020)

Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose
por: Schaefer, Benedikt, et al.
Publicado: (2021)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF
por: McEwan, Phil, et al.
Publicado: (2021)

Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up
por: Lacquaniti, Antonio, et al.
Publicado: (2020)

Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE‐ASIA‐HF)
por: Yeo, Tee Joo, et al.
Publicado: (2015)

Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
por: McMurray, John J V, et al.
Publicado: (2014)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia
por: Calleja, José Luis, et al.
Publicado: (2015)

Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose
por: Toblli, Jorge Eduardo, et al.
Publicado: (2014)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_31c6cmgf1j3l8s04ah50msqrt6